Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
We're delighted to introduce you to our first stand at the #ImmunologySummit2021 Innovation Centre; The Learning Revolution Register for free TODAY for more information
— UCB News (@ucb_news) 14.05.2021 -
Our second wave of speakers for the #ImmunologySummit2021 has been announced! This event is completely FREE. Register NOW!
— UCB News (@ucb_news) 12.05.2021 -
We’re so proud that SBTi has validated the targets we set ourselves for reducing our greenhouse gas emissions. Read why we feel making a commitment to limiting global warming is so important https://t.co/cYrO0PXq5d
— UCB News (@ucb_news) 11.05.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
